百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Beneficiaries

22 Dec 2019

Safeguarding well-being through biomedical science - Named Professorship Scheme promotes excellence in research

Technological innovation holds great promise for the medical field, and one of the top scientists at CityUHK is dedicated to bridging these two domains.

Professor Michael Yang Mengsu

Yeung Kin Man Chair Professor of Biomedical Sciences
Senior Vice-President (Innovation and Enterprise)
Director (Tung Biomedical Sciences Centre)
Director (Biotechnology & Health Centre)

Full Story

Professor Michael Yang Mengsu, Yeung Kin Man Chair Professor of Biomedical Sciences, is seeking to improve people’s lives by converting his research into clinical applications.

“The ultimate goal of biomedical research is to contribute to human well-being. We hope to encourage more students to find and develop their passions for research and innovation and cultivate an entrepreneurial mindset for the challenge of converting CityUHK’s many high-quality research projects into clinical applications that benefit society,” Professor Yang said.

Professor Yang’s research activities focus on the study of the biological processes involved in cancer and the development of biochip technology and nanotechnology for molecular diagnostics and therapeutic applications. He has published more than 200 peer-reviewed papers, received 30 US / China patents and co-founded three spin-off biotech companies since joining CityUHK in 1994. He was awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, the Hong Kong Technological Achievement Grand Award in 2007, the Natural Science Award by the Ministry of Education in 2015, and the Wuxi AppTech Life Science and Chemistry Award in 2016.

His latest work won a Gold Medal for a microfluidicsbased technology platform for disease diagnosis and drug screening at the 47th International Exhibition of Invention of Geneva in Switzerland in April 2019. The microfluidic chips can be used for the sensitive detection of multiple gene mutations on barcoded microbead arrays.

This process enables the early identification of infectious pathogens and tumour cells. The platform can also be used to generate arrays of single cells and tumour spheroids for screening the most efficient anti-cancer drugs with their optimal dosages. The patented technology has been licensed to a CityUHK spin-off company that was co-founded recently by three PhD students who graduated from Professor Yang’s laboratory.

Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis
“Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis”, developed by a research team led by Professor Michael Yang Mengsu.

 

Professor Yang has already turned several research projects into clinical applications. His group previously developed DNA chip technology for the early detection of cervical cancer. That application has been commercialised by a Shenzhen-based company co-founded in 2004 by one of his PhD graduates. Millions of women have benefited from the breakthrough. In addition, a company he helped establish with a PhD graduate and a post-doctoral fellow in Hong Kong in 2010 provides pharmacogenomics and assessment services for side effects from drugs and then suggests relevant preventive measures.

He thanked Dr Yeung Kin-man for supporting the Named Professorship Scheme. With the support of donors, this new scheme aims to promote excellence in research and professional education in the University’s distinguished research areas.

Dr and Mrs Yeung Kin-man
Dr and Mrs Yeung Kin-man at the donation ceremony in 2015. Dr Yeung’s donation supports University’s strategic developments and is used to establish Yeung Kin-man Chair Professorships in the University’s distinguished areas. In addition to biomedical sciences, the areas include
finance, IT innovation and management, media art and neuroscience.

 

These areas include architecture, behavioural and policy sciences, biomedical sciences, data science, data engineering, energy and environment, engineering, environmental veterinary medicine, finance, international economics, information engineering, IT innovation and management, media art, nanomaterials, neuroscience, nuclear engineering, translational neuroscience, and One Health.

“Donations have enabled my students and me to carry out pioneering biomedical research and innovations. We will continue to work hard to develop new technologies that benefit more and more people,” he said.

Research in CityUHK Biomedical Sciences brings new hope and opportunities


In addition to Professor Yang’s efforts to improve people’s lives by converting his research into clinical applications, faculty in CityUHK’s Department of Biomedical Sciences are dedicated to contributing to human betterment through their pioneering research. Associate Professor Dr Yao Xi developed a world-first, self-healable, anti-smudge coating, which enhances medical and aerospace equipment (details); Assistant Professor Dr Chow Kwan-ting studied rare cells that provide insights into developing cancer immunotherapy (details); and Assistant Professor Dr Ban Ki-won developed the first dual stem cell therapy for cardiac repair (details). These research achievements in biomedical science bring new hope and promise new opportunities for safeguarding human well-being.

网络赌博| 乐九| 百家乐官网玩法开户彩公司| 财神百家乐的玩法技巧和规则| 大发888最新官方网址| 尊爵线上娱乐| 百家乐金币游戏| 百家乐网络赌博真假| 大发888真钱帐户注册| 玉田县| 百家乐官网麻将牌| 太阳城伞| 百家乐官网德州扑克轮盘| 作弊百家乐官网赌具价格| 百家乐分享| 博彩赌场| 成都百家乐官网牌具| 大发888棋牌乐城下载| 百家乐官网官方游戏| 威尼斯人娱乐城官方站| 百家乐官网风云论坛| 做生意摆放老虎好不好| 丹东亿酷棋牌世界官方下载| 百家乐官网桌子北京| 金宝博备用网址| 八卦24山叫什么意思是什么| 包赢百家乐的玩法技巧和规则| 百家乐官网上分器定位器| 456棋牌游戏| 赌博百家乐官网的玩法技巧和规则 | 百家乐官网单机游戏下| 全讯网ceo| 百家乐三珠连跳打法| 平顶山市| 百家乐巴厘岛上海在线| 百家乐官网游戏机分析仪| 百家乐官网平注法亏损| 百家乐官网代理每周返佣| tt娱乐城clega| 百家乐使用技法| 百家乐官网硬币打法|